A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Vista sencilla de ítem
dc.creatorGordon, David E.
dc.creatorJang, Gwendolyn M.
dc.creatorBouhaddou, Mehdi
dc.creatorXu, Jiewei
dc.creatorObernier, Kirsten
dc.creatorWhite, Kris M.
dc.creatorO’Meara, Matthew J.
dc.creatorRezelj, Veronica V.
dc.creatorGuo, Jeffrey Z.
dc.creatorSwaney, Danielle L.
dc.creatorTummino, Tia A.
dc.creatorHuettenhain, Ruth
dc.creatorHuettenhain, Ruth
dc.creatorKaake, Robyn M.
dc.creatorRichards, Alicia L.
dc.creatorTutuncuoglu, Beril
dc.creatorFoussard, Helene
dc.creatorBatra, Jyoti
dc.creatorHaas, Kelsey
dc.creatorModak, Maya
dc.creatorKim, Minkyu
dc.creatorHaas, Paige
dc.creatorPolacco, Benjamin J.
dc.creatorBraberg, Hannes
dc.creatorFabius, Jacqueline M.
dc.creatorEckhardt, Manon
dc.creatorSoucheray, Margaret
dc.creatorBennett, Melanie J.
dc.creatorCakir, Merve
dc.creatorMcGregor, Michael J.
dc.creatorLi, Qiongyu
dc.creatorMeyer, Bjoern
dc.creatorRoesch, Ferdinand
dc.creatorVallet, Thomas
dc.creatorMac Kain, Alice
dc.creatorMiorin, Lisa
dc.creatorMoreno, Elena
dc.creatorNaing, Zun Zar Chi
dc.creatorZhou, Yuan
dc.creatorPeng, Shiming
dc.creatorShi, Ying
dc.creatorZhang, Ziyang
dc.creatorShen, Wenqi
dc.creatorKirby, Ilsa T.
dc.creatorMelnyk, James E.
dc.creatorChorba, John S.
dc.creatorLou, Kevin
dc.creatorDai, Shizhong A.
dc.creatorBarrio-Hernandez, Inigo
dc.creatorMemon, Danish
dc.creatorHernandez-Armenta, Claudia
dc.creatorLyu, Jiankun
dc.creatorMathy, Christopher J.P.
dc.creatorPerica, Tina
dc.creatorPilla, Kala B.
dc.creatorGanesan, Sai J.
dc.creatorSaltzberg, Daniel J.
dc.creatorRakesh, Ramachandran
dc.creatorLiu, Xi
dc.creatorRosenthal, Sara B.
dc.creatorCalviello, Lorenzo
dc.creatorVenkataramanan, Srivats
dc.creatorLiboy-Lugo, Jose
dc.creatorLin, Yizhu
dc.creatorHuang, Xi Ping
dc.creatorLiu, Yong Feng
dc.creatorWankowicz, Stephanie A.
dc.creatorBohn, Markus
dc.creatorSafari, Maliheh
dc.creatorUgur, Fatima S.
dc.creatorKoh, Cassandra
dc.creatorSavar, Nastaran Sadat
dc.creatorTran, Quang Dinh
dc.creatorShengjuler, Djoshkun
dc.creatorFletcher, Sabrina J.
dc.creatorO’Neal, Michael C.
dc.creatorCai, Yiming
dc.creatorChang, Jason C.J.
dc.creatorBroadhurst, David J.
dc.creatorKlippsten, Saker
dc.creatorSharp, Phillip P.
dc.creatorWenzell, Nicole A.
dc.creatorKuzuoglu, Duygu
dc.creatorWang, Hao Yuan
dc.creatorTrenker, Raphael
dc.creatorYoung, Janet M.
dc.creatorCavero, Devin A.
dc.creatorHiatt, Joseph
dc.creatorRoth, Theodore L.
dc.creatorRathore, Ujjwal
dc.creatorSubramanian, Advait
dc.creatorNoack, Julia
dc.creatorHubert, Mathieu
dc.creatorStroud, Robert M.
dc.creatorFrankel, Alan D.
dc.creatorRosenberg, Oren S.
dc.creatorVerba, Kliment A.
dc.creatorAgard, David A.
dc.creatorOtt, Melanie
dc.creatorEmerman, Michael
dc.creatorJura, Natalia
dc.creatorvon Zastrow, Mark
dc.creatorVerdin, Eric
dc.creatorAshworth, Alan
dc.creatorSchwartz, Olivier
dc.creatord’Enfert, Christophe
dc.creatorMukherjee, Shaeri
dc.creatorJacobson, Matt
dc.creatorMalik, Harmit S.
dc.creatorFujimori, Danica G.
dc.creatorIdeker, Trey
dc.creatorCraik, Charles S.
dc.creatorFloor, Stephen N.
dc.creatorFraser, James S.
dc.creatorGross, John D.
dc.creatorSali, Andrej
dc.creatorRoth, Bryan L.
dc.creatorRuggero, Davide
dc.creatorTaunton, Jack
dc.creatorKortemme, Tanja
dc.creatorBeltrao, Pedro
dc.creatorVignuzzi, Marco
dc.creatorGarcía-Sastre, Adolfo
dc.creatorShokat, Kevan M.
dc.creatorShoichet, Brian K.
dc.creatorKrogan, Nevan J.
dc.date.accessioned2020-07-21T19:25:22Z
dc.date.available2020-07-21T19:25:22Z
dc.date.created2020-04-30
dc.description.abstractenglishA newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals and caused worldwide social and economic disruption1,2. There are no antiviral drugs with proven clinical efficacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and efforts to develop drugs and vaccines are hampered by the limited knowledge of the molecular details of how SARS-CoV-2 infects cells. Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins that physically associated with each of the SARS-CoV-2 proteins using affinity-purification mass spectrometry, identifying 332 high-confidence protein–protein interactions between SARS-CoV-2 and human proteins. Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clinical trials and 28 are preclinical compounds). We screened a subset of these in multiple viral assays and found two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors. Further studies of these host-factor-targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.spa
dc.format.extent30 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1038/s41586-020-2286-9spa
dc.identifier.issn1476-4687spa
dc.identifier.otherhttps://www.nature.com/articles/s41586-020-2286-9spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/10883
dc.publisherScience Directeng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleA SARS-CoV-2 protein interaction map reveals targets for drug repurposingspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
s41586-020-2286-9.pdf
Tamaño:
10.51 MB
Formato:
Adobe Portable Document Format
Descripción:
Documento reservado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS